JP2007516966A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007516966A5 JP2007516966A5 JP2006542741A JP2006542741A JP2007516966A5 JP 2007516966 A5 JP2007516966 A5 JP 2007516966A5 JP 2006542741 A JP2006542741 A JP 2006542741A JP 2006542741 A JP2006542741 A JP 2006542741A JP 2007516966 A5 JP2007516966 A5 JP 2007516966A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cancer
- synthetic peptide
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 110
- 239000003814 drug Substances 0.000 claims 56
- 206010028980 Neoplasm Diseases 0.000 claims 55
- 201000011510 cancer Diseases 0.000 claims 55
- 230000002163 immunogen Effects 0.000 claims 44
- 239000012634 fragment Substances 0.000 claims 42
- 210000004027 cell Anatomy 0.000 claims 39
- 239000000203 mixture Substances 0.000 claims 39
- 210000002865 immune cell Anatomy 0.000 claims 36
- 229940079593 drug Drugs 0.000 claims 34
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 27
- 208000032839 leukemia Diseases 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 14
- 210000004443 dendritic cell Anatomy 0.000 claims 10
- 230000028993 immune response Effects 0.000 claims 10
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 9
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 9
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 7
- 208000026310 Breast neoplasm Diseases 0.000 claims 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 7
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 206010027406 Mesothelioma Diseases 0.000 claims 7
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 7
- 206010057644 Testis cancer Diseases 0.000 claims 7
- 230000015572 biosynthetic process Effects 0.000 claims 7
- 201000005202 lung cancer Diseases 0.000 claims 7
- 208000020816 lung neoplasm Diseases 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 201000003120 testicular cancer Diseases 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 210000002798 bone marrow cell Anatomy 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 6
- 210000002540 macrophage Anatomy 0.000 claims 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 6
- 102000009027 Albumins Human genes 0.000 claims 4
- 108010088751 Albumins Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 102000040856 WT1 Human genes 0.000 claims 4
- 108700020467 WT1 Proteins 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 claims 3
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 230000001900 immune effect Effects 0.000 claims 3
- 239000012642 immune effector Substances 0.000 claims 3
- 230000008105 immune reaction Effects 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000037029 cross reaction Effects 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 230000004963 pathophysiological condition Effects 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52595503P | 2003-12-01 | 2003-12-01 | |
| PCT/US2004/040347 WO2005053618A2 (en) | 2003-12-01 | 2004-11-30 | Synthetic hla binding peptide analogues and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007516966A JP2007516966A (ja) | 2007-06-28 |
| JP2007516966A5 true JP2007516966A5 (enExample) | 2008-01-17 |
Family
ID=34652399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006542741A Pending JP2007516966A (ja) | 2003-12-01 | 2004-11-30 | 合成ｈｌａ結合ペプチド類似体及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7488718B2 (enExample) |
| EP (2) | EP2478913A1 (enExample) |
| JP (1) | JP2007516966A (enExample) |
| AU (1) | AU2004294345B2 (enExample) |
| CA (1) | CA2548135C (enExample) |
| ES (1) | ES2402184T5 (enExample) |
| WO (1) | WO2005053618A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2478913A1 (en) * | 2003-12-01 | 2012-07-25 | Sloan-Kettering Institute For Cancer Research | Synthetic HLA binding peptide analogues and uses thereof |
| US20060127409A1 (en) * | 2003-12-01 | 2006-06-15 | Scheinberg David A | Bcr-abl vaccines and methods of use thereof |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| EP2010209B1 (en) * | 2006-04-10 | 2016-06-15 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| JP2010504332A (ja) * | 2006-09-19 | 2010-02-12 | ヒューマン バイオモレキュラル リサーチ インスティテュート | アルツハイマー病の診断方法及び遺伝子マーカー |
| MY158219A (en) * | 2007-02-27 | 2016-09-15 | Int Inst Cancer Immunology Inc | Method for activation of helper t cell and composition for use in the method |
| JPWO2009066462A1 (ja) * | 2007-11-20 | 2011-04-07 | 日本電気株式会社 | 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン |
| TWI504407B (zh) * | 2007-12-05 | 2015-10-21 | Int Inst Cancer Immunology Inc | 癌疫苗組合物 |
| WO2009137872A1 (en) * | 2008-05-14 | 2009-11-19 | Simons Haplomics Limited | Methods and compositions for the treatment of cancer |
| AU2011293522B2 (en) | 2010-08-24 | 2015-03-19 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| WO2013018778A1 (ja) | 2011-07-29 | 2013-02-07 | 独立行政法人理化学研究所 | ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物 |
| US9539299B2 (en) * | 2011-10-27 | 2017-01-10 | International Institute Of Cancer Immunology, Inc. | Combination therapy with WT1 peptide vaccine and temozolomide |
| EP3520810A3 (en) * | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
| AU2013337247B2 (en) | 2012-11-05 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| PL2945647T3 (pl) | 2013-01-15 | 2021-03-08 | Memorial Sloan Kettering Cancer Center | Immunogenne peptydy wt-1 i sposoby ich zastosowania |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
| RS63561B1 (sr) | 2015-11-20 | 2022-10-31 | Memorial Sloan Kettering Cancer Center | Kompozicija za lečenje raka |
| WO2018039203A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating multiple myeloma |
| US20190209669A1 (en) | 2016-08-23 | 2019-07-11 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating breast cancer |
| EP3549957A4 (en) | 2016-11-30 | 2020-08-05 | Sumitomo Dainippon Pharma Co., Ltd. | AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| US20210100886A1 (en) | 2017-03-30 | 2021-04-08 | Sumitomo Dainippon Pharma Co., Ltd. | Wt1 cancer antigen peptides and peptide conjugates comprising the peptides |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物 |
| WO2019083960A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| CN111465411A (zh) | 2017-10-24 | 2020-07-28 | 恩科佩普股份有限公司 | 用于治疗乳腺癌的肽疫苗和派姆单抗 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| JP7162675B2 (ja) | 2018-09-28 | 2022-10-28 | 住友ファーマ株式会社 | 注射用組成物 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3942042A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| MX2022014249A (es) * | 2020-05-12 | 2023-02-22 | Sumitomo Pharma Co Ltd | Composición farmacéutica para tratar el cáncer. |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| EP4385519A4 (en) | 2021-08-12 | 2025-08-06 | Int Inst Cancer Immunology Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING OR PREVENTING CANCER |
| CN114149970B (zh) * | 2021-11-09 | 2024-06-18 | 因诺伟(北京)生物医疗科技有限公司 | 一种外周血造血干细胞来源致敏树突状细胞的制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156316A (en) * | 1995-05-08 | 2000-12-05 | Sloan-Kettering Institute For Cancer Research | Oncogene fusion protein peptide vaccines |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| GB9823897D0 (en) * | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| AU2001247220A1 (en) * | 2000-02-22 | 2001-09-03 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| EP2478913A1 (en) * | 2003-12-01 | 2012-07-25 | Sloan-Kettering Institute For Cancer Research | Synthetic HLA binding peptide analogues and uses thereof |
-
2004
- 2004-11-30 EP EP11189059A patent/EP2478913A1/en not_active Withdrawn
- 2004-11-30 CA CA2548135A patent/CA2548135C/en not_active Expired - Lifetime
- 2004-11-30 US US10/999,425 patent/US7488718B2/en active Active
- 2004-11-30 ES ES04812790.6T patent/ES2402184T5/es not_active Expired - Lifetime
- 2004-11-30 JP JP2006542741A patent/JP2007516966A/ja active Pending
- 2004-11-30 WO PCT/US2004/040347 patent/WO2005053618A2/en not_active Ceased
- 2004-11-30 AU AU2004294345A patent/AU2004294345B2/en not_active Expired
- 2004-11-30 EP EP04812790.6A patent/EP1708732B2/en not_active Expired - Lifetime
-
2005
- 2005-09-12 US US11/223,139 patent/US7598221B2/en active Active
-
2009
- 2009-10-06 US US12/574,555 patent/US20100239547A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007516966A5 (enExample) | ||
| JP4480580B2 (ja) | Ｗｔ１置換型ペプチド | |
| DK2547364T3 (en) | Peptides, conjugates and methods for increasing the immunogenicity of a vaccine | |
| ES2676630T3 (es) | Control inmunogénico de tumores y células tumorales | |
| JP6367950B2 (ja) | 前立腺癌治療用組成物 | |
| JP6266811B2 (ja) | 血管新生病の免疫療法 | |
| TWI353250B (en) | Glp-1 pharmaceutical compositions | |
| TWI455721B (zh) | 癌疫苗組合物 | |
| WO2005095598A1 (ja) | Ｗｔ１由来の癌抗原ペプチド | |
| AU2015204503A1 (en) | Novel vaccines against HPV and HPV-related diseases | |
| JP2000502327A (ja) | ジフテリア毒素のエピトープ | |
| ES2805829T3 (es) | Péptido derivado de GPC3, composición farmacéutica para el tratamiento o la prevención de cáncer usando el mismo, inductor de inmunidad y método para producir células presentadoras de antígeno | |
| BRPI0708737A2 (pt) | mÉtodo de prevenÇço ou reduÇço do risco ou incidÊncia de cÂncer utilizando-se peptÍdeos baseados na proteÍna na cadeia neural | |
| CN109718363B (zh) | 预防、缓解或治疗阿尔茨海默病的肽及其应用 | |
| TW201000119A (en) | MYBL2 epitope peptides and vaccines containing the same | |
| CN113491766A (zh) | 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法 | |
| CN101072875B (zh) | 新型癌抗原肽及其用途 | |
| US11033609B2 (en) | Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis | |
| TWI496579B (zh) | 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途 | |
| WO2015148831A1 (en) | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide | |
| JP2001514659A (ja) | ドラスタチン−１５誘導体とタキサンとの併用 | |
| JP2002538166A (ja) | Ｍｈｃクラスｉｉによって提示されるｍａｇｅ−３由来免疫原性ペプチドおよびその使用 | |
| CN114129711B (zh) | 度拉糖肽在制备抗肿瘤药物中的应用 | |
| US11712466B2 (en) | Vaccine composition | |
| WO2008151512A1 (fr) | Dérivés de calcitonine de saumon linéaires, pégylés, spécifiques de site |